Marc Berger

Marc L. Berger, MD, is a retired, part-time consultant. He recently agreed to Chair the Real World Evidence Product Advisory Board for SHYFT Analytics. Until July 2017, he was Vice President, Real World Data and Analytics (RWDnA) at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company; and Vice President, Outcomes Research and Management at Merck & Co., Inc. During his career in industry, he has been involved with all aspects of drug development and commercialization including the design and execution of Phase 2/3/4 clinical trials, real world data studies, and market access strategies.

Marc has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for CMS, the steering committee for the AHRQ Centers for Research and Education on Therapeutics (CERTs), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Advisory Council for North America (ACNA) of the DIA, the editorial advisory board of Value in Health and has chaired the Innovative Technology Advocacy Committee of PhRMA.

Marc Berger is the Chair, Real World Evidence Product Advisory Board at SHYFT, based in New York, New York, United States, North America. With a background in Life Science, Marc Berger has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.